In a study of 77 recurrent glioblastoma patients, Urup et al. presented that low methylation of the CEBP binding region in the AGT promoter is significantly associated with poor response to Bevacizumab (Avastin/Ava) combination treatment, while improved response to this therapy is correlated with enhanced survival [63]. The gene discussed is AGT; the disease is glioblastoma.